FDA Moves to Real-Time Clinical Trial Patient Monitoring, Faster Drug Review

Follow Drugslib on

By Deanna Neff HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on April 29, 2026.

via HealthDay

WEDNESDAY, April 29, 2026 — The U.S. Food and Drug Administration (FDA) is moving to speed drug development and review by launching real-time clinical trials.

The move could soon mean more options for patients who need life-saving medications.

The agency announced Tuesday that it has completed the first tests of a system that allows FDA scientists to see safety and effectiveness data from patients as it is collected.

This shift aims to turn the traditional, stop-and-go process of drug testing and reporting into a continuous stream of live data.

Drug development now happens in distinct stages. When one phase ends, there is often a long pause while researchers compile data to report to the FDA and wait for approval to start the next step.

By using artificial intelligence and modern data science, the FDA hopes to eliminate these gaps entirely.

“For 60 years, we've been conducting clinical trials in the same way, where key data signals can take years to reach the FDA. The lag time can delay regulatory decisions unnecessarily and slow down the drug development timeline,” FDA Commissioner Dr. Marty Makary said in a news release.

By seeing safety signals in real time, the FDA aims to identify potential risks or breakthrough successes immediately, rather than waiting for a final report months later.

The agency highlighted two trials already using this technology.

AstraZeneca is testing a treatment for mantle cell lymphoma, while Amgen is conducting a trial for small cell lung cancer. In both cases, the drug developers are sharing live signals with the FDA, showing that the technology appears ready for the mainstream.

The technology they're using is embeded into workflows at hospitals through companies like Paradigm Health. Its AI-powered platform was used for AstraZeneca's multi-site lymphoma trial, capturing data directly from a patient's electronic health record and other sources, and reported to the FDA in real time.

Jeremy Walsh, the FDA’s chief AI officer, said the human cost of waiting for data is too high.

“Real-time trials have been talked about for years," he said. "We demonstrated that it is not only possible, but also potentially transformative for the clinical trials ecosystem.”

The FDA has released a Request for Information to help design a larger pilot program launching this summer. The agency is looking for feedback from scientists and drug makers through May 29, to ensure the system is both efficient and secure.

Sources

  • U.S. Food and Drug Administration, news release, April 28, 2026
  • Paradigm Health, news release, April 28, 2026

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2026-04-30 02:19

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords